Document:

Exhibit 4.2

 

NEITHER THIS WARRANT NOR THE SHARES
OF COMMON STOCK UNDERLYING THIS WARRANT OF BLONDER TONGUE LABORATORIES, INC. (THE “COMPANY”) HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD,
ASSIGNED OR TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAW AND SUCH SALE OR TRANSFER IS MADE IN ACCORDANCE WITH SUCH REGISTRATION STATEMENT AND ANY OTHER APPLICABLE STATE
SECURITIES LAW OR (ii) THE COMPANY RECEIVES A WRITTEN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL TO THE HOLDER OF SUCH
WARRANT (OR SUCH UNDERLYING SHARES OF COMMON STOCK), PROVIDED SUCH OTHER COUNSEL IS REASONABLY SATISFACTORY TO THE COMPANY, THAT
SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER MAY BE MADE WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS. 

 

Date: December 14, 2020

 

WARRANT TO PURCHASE ______ SHARES OF
COMMON STOCK

OF

BLONDER TONGUE LABORATORIES, INC.

 

THIS CERTIFIES that,
for value received, ___________________, an individual (the “Holder”), is entitled to purchase from Blonder
Tongue Laboratories, Inc., a Delaware corporation (the “Company”), _________________________________________
(______) (“Warrant Shares”) fully paid, validly issued and non-assessable unregistered shares of common stock
of the Company, $.001 par value per share (the “Common Stock”), subject to adjustment as provided herein, at
a purchase price of $0.70 per share (“Exercise Price”), subject to the vesting requirements set forth in Section
1 below.

 

1. Vesting. The
purchase rights under this Warrant shall vest for all of the Warrant Shares upon the issuance of this Warrant and shall be exercisable
beginning at such time as either (i) Stockholder Approval (defined below) has been obtained, or (ii) all of the Cavalry Transaction
Warrants (defined below) have been exercised or have expired by their terms, and continuing thereafter until 5:00 p.m. on December
14, 2025 (the “Exercise Period”).

 

For purposes of this Warrant, (i) the “Cavalry
Transaction Warrants” shall mean and refer to the aggregate common stock purchase warrants to purchase up to 714,286
shares of the Company’s Common Stock, issued and delivered pursuant to that certain Securities Purchase Agreement, dated
as of December 14, 2020, between the Company and each “Purchaser” (as defined therein) party thereto, with respect
to, among other things, the purchase of $1,000,000 of the Company’s Common Stock (the “Securities Purchase Agreement”),
and (ii) “Stockholder Approval” shall mean such approval as may be required by the applicable rules and regulations
of the NYSE American (or any successor entity) from the stockholders of the Company with respect to the transactions contemplated
by the Securities Purchase Agreement (and the other agreements, documents and instruments contemplated thereby and collateral thereto),
including the issuance of shares of the Company's Common Stock in excess of 19.99% of the issued and outstanding Common Stock on
the closing date under the Securities Purchase Agreement, as such Stockholder Approval is required to be obtained pursuant to the
Securities Purchase Agreement.

 

The Company shall use
commercially reasonable efforts to provide the Holder with notice promptly (i) after the Company obtains Stockholder Approval,
and/or (ii) after all of the Cavalry Transaction Warrants have been exercised or have expired.

 

2. Exercise of Warrant.
This Warrant may be exercised in whole or in part (but not as to fractional shares and only with respect to properly vested purchase
rights) during the Exercise Period by the surrender of the Warrant, with the “Warrant Exercise and Purchase Agreement”
attached hereto as Rider A properly completed and duly executed, at the principal office of the Company at One Jake Brown
Road, Old Bridge, New Jersey 08857, or such other location which shall at that time be the principal office of the Company, and
upon payment to the Company of the Exercise Price multiplied by the number of shares to be purchased upon such exercise. The Exercise
Price shall be paid in immediately available funds to the order of the Company by cashier’s check, certified check or wire
transfer. Upon receipt thereof, the Company shall, as promptly as practicable, execute or cause to be executed and deliver to the
Holder a certificate or certificates as the Holder shall designate representing the number of shares represented by the Holder’s
exercise or in the alternative by the issuance of book-entry shares. Unless and until such time as the Warrant Shares have been
registered under the Securities Act of 1933, as amended (“Securities Act”), certificates representing such Warrant
Shares shall bear restrictive legends. The stock certificate or certificates so delivered shall be in such denominations as may
be specified in said notice and shall be registered in the name of the Holder or in such other name as shall be designated in such
notice. This Warrant shall be deemed to have been exercised and such certificate or certificates shall be deemed to have been issued
and the Holder or such other person so designated shall be deemed to have become a holder of record of such shares for all purposes,
as of the date said notice and payment in full is received by the Company. Unless this Warrant has expired, if this Warrant shall
have been exercised only in part, a new Warrant of like tenor and for such number of shares as the Holder shall direct, representing
in the aggregate the right to purchase a number of shares with respect to which this Warrant shall not have been exercised, shall
also be issued to the Holder within such time.

 

     

     

    

 

3. Transfer/Warrant
Shares Legend. This Warrant and the rights hereunder shall be non-transferrable, except as permitted by and in compliance with
applicable law. Each certificate representing Warrant Shares shall contain a legend in substantially the following form:

 

THE SHARES OF COMMON STOCK OF BLONDER TONGUE
LABORATORIES, INC. (THE “COMPANY”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT WITH
RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAW AND SUCH SALE OR TRANSFER IS MADE IN ACCORDANCE
WITH SUCH REGISTRATION STATEMENT AND ANY OTHER APPLICABLE STATE SECURITIES LAW OR (ii) THE COMPANY RECEIVES A WRITTEN OPINION OF
COUNSEL TO THE COMPANY OR OTHER COUNSEL TO THE HOLDER OF SUCH SHARES OF COMMON STOCK, PROVIDED SUCH OTHER COUNSEL IS REASONABLY
SATISFACTORY TO THE COMPANY, THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER MAY BE MADE WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

4. Certain Covenants
of the Company. The Company covenants and agrees that all shares which may be issued upon the exercise of this Warrant, will,
upon issuance, be duly and validly issued, fully paid and nonassessable. The Company covenants and agrees that during the Exercise
Periods the Company will at all times have authorized, and reserved for the purpose of issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented
by this Warrant.

 

5. Anti-Dilution Provisions.
The number and character of the shares underlying this Warrant shall be subject to adjustment only as provided in this Section
5. In the event of a stock split, stock dividend, reverse stock split or combination of the Common Stock of the Company, an equitable
adjustment shall be made by the Company in the number of shares for which this Warrant has been issued with respect thereto, and
the Exercise Price which must be paid therefor, provided that no such adjustment shall either (i) diminish the proportionate interest
of the Holder prior to the occurrence of the event or (ii) increase the aggregate Exercise Price to be paid by the Holder upon
exercise of the Warrant in full. In addition, in case at any time and from time to time during the Exercise Periods, the Company
shall be a party to any transaction, including, without limitation, a merger, consolidation, liquidation, combination, reorganization
or recapitalization of the Common Stock (each, a “Transaction”), in which the previously outstanding common
stock of the Company shall be changed into or exchanged for different securities of the Company or common stock or other securities
of another corporation (collectively, “Acquiror Common Stock”) or other property (including cash) or any combination
of the foregoing, then in such event: (i) the Warrant shall become fully exercisable notwithstanding the date of the event and
(ii) as often as such event shall occur, as a condition of the consummation of the Transaction, the Company or the surviving company,
as the case may be, shall make lawful and adequate provision so that the Holder, upon the exercise thereof at any time on or after
the consummation of the Transaction during the Exercise Periods, shall be entitled to receive, and the Warrant shall thereafter
represent the right to receive, in lieu of the common stock issuable upon such conversion prior to such consummation (determined
on a fully vested basis), the securities or other property to which the Holder would have been entitled upon consummation of the
Transaction if the Holder had exercised such Warrant immediately prior thereto. There shall be no preemptive rights associated
with the Warrant or the Warrant Shares issuable thereunder.

 

6. Reserved.

 

7. Notice of Adjustments.
Whenever any of the number of shares of Common Stock purchasable or Exercise Price to be paid under the terms of this Warrant shall
be adjusted pursuant to Section 5 hereof, the Company shall notify the Holder at the Holder’s last address known to the Company.

 

8. Fractional Shares.
No fractional shares of the Company’s Common Stock will be issued in connection with any purchase hereunder but in lieu of
such fractional shares, the Company shall make a cash refund therefor equal in amount to the product of the applicable fraction
multiplied by the Exercise Price.

 

    2

     

    

 

9. Registration Rights.

 

(a) Piggyback
Rights. If the Company proposes to register any of its Common Stock under the Securities Act in connection with the
public offering of such securities solely for cash (other than in (i) a registration relating to the sale of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration
relating to a transaction under Rule 145 promulgated by the Securities and Exchange Commission (“SEC”) under the
Securities Act; (iii) a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities (as defined below); (iv)
a registration in connection with an offering pursuant to which the Company is seeking to receive less than $2,500,000), the
Company shall, at such time, promptly give the Holder notice of such registration. Upon the request of the Holder, given
within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection
9(b), cause to be registered (x) all of the Common Stock issuable or issued upon exercise of this Warrant and (y) any
Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued
as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clause (x) above (collectively, “Registrable Securities”) that the Holder has requested to be included in
such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section
9 before the effective date of such registration, whether or not the Holder has elected to include Registrable Securities
in such registration. The expenses (other than Selling Expenses (as defined below)) of such withdrawn registration shall be
borne by the Company in accordance with Subsection 9(d). 

 

(b) Underwriting
Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant
to Subsection 9(a), the Company shall not be required to include any of the Holder’s Registrable Securities in such
underwriting unless the Holder accepts the terms of the underwriting as agreed upon between the Company and its underwriters, and
then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering
by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering
only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering.

 

(c) Furnish Information.
It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 9 with respect
to the Registrable Securities of the Holder that the Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect
the registration of the Holder’s Registrable Securities.

 

(d) Expenses of
Registration. All expenses (other than underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for the Holder (collectively, “Selling Expenses”))
incurred in connection with registrations, filings, or qualifications pursuant to Section 9, including all registration,
filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company shall be
borne and paid by the Company.

 

(e) Delay of Registration.
Holder shall not have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to
this Warrant as the result of any controversy that might arise with respect to the interpretation or implementation of this Section
9.

 

    3

     

    

 

(f) Indemnification.
If any Registrable Securities are included in a registration statement under this Section 9:

 

(i) To the extent permitted
by law, the Holder will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed
the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel
and accountants for the Company, any underwriter (as defined in the Securities Act), and any controlling Person of any such underwriter,
against any Damages (defined below), in each case only to the extent that such Damages arise out of or are based upon actions or
omissions made in reliance upon and in conformity with written information furnished by or on behalf of the Holder expressly for
use in connection with such registration; and the Holder will pay to the Company and each other aforementioned Person any legal
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which
Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection
9(f) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld. For purposes of this Section 9, “Damages”
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act,
the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof)
arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration
statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make
the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents
or affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the
Securities Act, the Exchange Act, or any state securities law.

 

(ii) Promptly after receipt
by an indemnified party under this Subsection 9(f) of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Subsection 9(f), give the indemnifying party notice of the commencement
thereof. The indemnifying party shall have the right to participate in such action and to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the
fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by
the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and
any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable
time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under
this Subsection 9(f), to the extent that such failure materially prejudices the indemnifying party’s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Subsection 9(f).

 

(iii) Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

(iv) Unless otherwise
superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the
Company and the Holder under this Subsection 9(f) shall survive the completion of any offering of Registrable Securities
in a registration under this Section 9, and otherwise shall survive the termination of this Warrant.

 

(g) Termination
of Registration Rights. The right of the Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Subsection 9(a) shall terminate upon such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of the Holder’s shares.

 

    4

     

    

 

10. Charges, Taxes
and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by
the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the
Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than
the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by a form of assignment acceptable to the
Company duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
it for any transfer tax incidental thereto.

 

11. Investment Representations.
By accepting this Warrant, the Holder represents and warrants to the Company that: (i) this Warrant is being acquired by the Holder
for the Holder’s own account for investment purposes only and (subject to the disposition of its property being at all times
within its control) not with a view to resale, distribution, or other disposition; (ii) any Warrant Shares which may be issued
to the Holder upon exercise of this Warrant will be acquired by the Holder for the Holder’s own account for investment purposes
only and (subject to the disposition of its property being at all times within its control) not with a view to resale, distribution,
or other disposition; (iii) the Holder is able to bear the economic risk of investment in this Warrant and the Warrant Shares,
can afford to sustain a total loss on such investment, and has such knowledge and experience in financial and business matters
that it is capable of evaluating the merits and risks of its proposed investment; (iv) when issued, and upon any exercise of the
Warrant, the Holder acknowledges that the Holder is and will be an “accredited investor” as such term is defined in
Rule 501(a) under the Securities Act; (v) the Holder understands that there is no public market for this Warrant, that there may
never be a public market for this Warrant, that in the future there may not be a public or liquid market for the Warrant Shares,
and, therefore, that the Holder may have to bear the risk of its investment in this Warrant and any Warrant Shares indefinitely;
and (vi) subject to Section 5 hereof, the Company shall not be required to issue any of the Warrant Shares unless such issuance
complies with the Securities Act and any applicable state or other securities laws. The Holder understands and acknowledges that
the Company is relying upon the accuracy and truthfulness of these representations and warranties to issue the Warrant and any
Warrant Shares to the Holder.

 

12. Loss, Theft, Destruction
or Mutilation. Upon receipt by the Company of evidence reasonably satisfactory to it that this Warrant has been mutilated,
destroyed, lost or stolen, and in the case of any destroyed, lost or stolen Warrant, a bond of indemnity reasonably satisfactory
to the Company, or in the case of a mutilated Warrant, upon surrender and cancellation thereof, the Company will execute and deliver
in the Holder’s name, in exchange and substitution for the Warrant so mutilated, destroyed, lost or stolen, a new Warrant
of like tenor substantially in the form thereof with appropriate insertions and variations.

 

13. No Stockholder
Rights. The Holder shall not by virtue hereof be entitled to any rights as a stockholder in the Company.

 

14. Definition of
Person. For purposes of this Warrant, “Person” means an individual, corporation, partnership, limited liability
company, trust or other entity.

 

15. Headings.
The descriptive headings of the several sections of this Warrant are inserted for convenience only and do not constitute a part
of this Warrant.

 

16. Governing Law.
This Warrant shall be governed by the substantive laws of the State of Delaware, without regard to principles of conflicts of law.

 

17. Amendment.
This Warrant may be amended, waived or terminated only by an instrument in writing signed by the Company and the Holder.

 

18. Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant

 

19. Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to the foregoing terms and conditions.

 

    5

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be signed by its duly authorized officer on the date of this Warrant.

 

	 	BLONDER TONGUE LABORATORIES, INC.
	 	 	 
	 	By:	 
	 	 	Edward R. Grauch, Chief Executive Officer

 & President
	 	 	 
	 	By:	 
	 	 	Eric Skolnik, Secretary

 

    6

     

    

 

RIDER A

 

TO

 

WARRANT TO PURCHASE _____ SHARES OF COMMON
STOCK

OF

BLONDER TONGUE LABORATORIES, INC.

 

WARRANT EXERCISE AND PURCHASE AGREEMENT

 

Date: _____________

 

TO:

 

The undersigned, pursuant to the provisions
set forth in the attached Warrant, hereby agrees to purchase _____________________________________ shares of Common Stock covered
by such Warrant, and makes payment herewith in full therefor at the price per share provided by this Warrant.

 

	 	By:	                     
	 	 	 

 

 

7Exhibit
4.3

 

NEITHER
THIS WARRANT NOR THE SHARES OF COMMON STOCK UNDERLYING THIS WARRANT OF BLONDER TONGUE LABORATORIES, INC. (THE “COMPANY”)
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND
MAY NOT BE PLEDGED, SOLD, ASSIGNED OR TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE
ACT AND ANY APPLICABLE STATE SECURITIES LAW AND SUCH SALE OR TRANSFER IS MADE IN ACCORDANCE WITH SUCH REGISTRATION STATEMENT AND
ANY OTHER APPLICABLE STATE SECURITIES LAW OR (ii) THE COMPANY RECEIVES A WRITTEN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL
TO THE HOLDER OF SUCH WARRANT (OR SUCH UNDERLYING SHARES OF COMMON STOCK), PROVIDED SUCH OTHER COUNSEL IS REASONABLY SATISFACTORY
TO THE COMPANY, THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER MAY BE MADE WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
ACT OR APPLICABLE STATE SECURITIES LAWS. 

 

Date:
December 14, 2020

 

WARRANT
(“Warrant”) TO PURCHASE _______ SHARES OF COMMON STOCK

OF

BLONDER
TONGUE LABORATORIES, INC.

 

THIS
CERTIFIES that, for value received, ________________, an individual (the “Holder”), is entitled to purchase
from Blonder Tongue Laboratories, Inc., a Delaware corporation (the “Company”), ________________________________________
(_______) (“Warrant Shares”) fully paid, validly issued and non-assessable unregistered shares of common stock
of the Company, $.001 par value per share (the “Common Stock”), subject to adjustment as provided herein, at
a purchase price of $1.25 per share (“Exercise Price”), subject to the vesting requirements set forth in Section
1 below.

 

1. Vesting.
The purchase rights under this Warrant shall vest on a pro rata basis, with, as and to the extent of the exercise of the Cavalry
Transaction Warrants (defined below), and shall be exercisable in each case on the fifth (5th) business
day following the business day on which the Company has received either (i) the Notice of Exercise (as defined in the Cavalry
Transaction Warrants), together with immediately available funds representing the proceeds derived from each and any such exercise
of the Cavalry Transaction Warrants, or (ii) the Notice of Exercise, with the appropriate notation thereon indicating that the
Purchaser is effecting the purchase through cancellation of a portion of the Cavalry Transaction Warrants in a “cashless
transaction” (each of (i) or (ii) above constituting “Cavalry Warrant Proceeds”). The calculation of
the aggregate Warrant Shares that have vested as of any date of measurement shall be determined based on the product obtained
by multiplying (A) by a fraction, the numerator of which is (B) and the denominator of which is (C) where:

 

(A)
= _______ (the aggregate number of Warrant Shares issuable upon exercise of this Warrant in accordance with the terms of this
Warrant, assuming all Warrant Shares are fully vested);

 

(B)
= the aggregate number of Cavalry Transaction Warrants that have been exercised from the original issuance date of the Cavalry
Transaction Warrants through the date of measurement (and for which the Cavalry Warrant Proceeds have been paid to and received
by the Company); and

 

(C)
= 714,286 (the aggregate number of Cavalry Transaction Warrants issued pursuant to the Securities Purchase Agreement (defined
below).

 

For
purposes of this Warrant, (i) the “Cavalry Transaction Warrants” shall mean and refer to the aggregate common
stock purchase warrants to purchase up to 714,286 shares of the Company’s Common Stock, issued and delivered pursuant to
that certain Securities Purchase Agreement, dated as of December 14, 2020, between the Company and each “Purchaser”
(as defined therein) party thereto, with respect to, among other things, the purchase of $1,000,000 of the Company’s Common
Stock (the “Securities Purchase Agreement”), and (ii) “Stockholder Approval” shall mean
such approval as may be required by the applicable rules and regulations of the NYSE American (or any successor entity) from the
stockholders of the Company with respect to the transactions contemplated by the Securities Purchase Agreement (and the other
agreements, documents and instruments contemplated thereby and collateral thereto), including the issuance of shares of the Company's
Common Stock in excess of 19.99% of the issued and outstanding Common Stock on the closing date under the Securities Purchase
Agreement, as such Stockholder Approval is required to be obtained pursuant to the Securities Purchase Agreement. The Company
shall use commercially reasonable efforts to provide the Holder with notice (i) of its receipt of Cavalry Warrant Proceeds within
three (3) business days following receipt thereof, including within such notice, the Company’s calculation of the aggregate
number of the Holder’s Warrant Shares that have vested as of such date and are then exercisable, (ii) promptly after the
Company obtains Stockholder Approval, and/or (ii) promptly after all of the Cavalry Transaction Warrants have been exercised or
have expired.

  

     

      

    

 

2. Exercise
of Warrant. This Warrant may be exercised in whole or in part (but not as to fractional shares and only with respect to properly
vested purchase rights as contemplated by Section 1 above) during the period commencing at such time as either (i) Stockholder
Approval (defined above) has been obtained, or (ii) all of the Cavalry Transaction Warrants have been exercised or have expired
by their terms, and continuing thereafter until 5:00 p.m. New York time on December 14, 2025 (the “Exercise Period”),
by the surrender of the Warrant, with the “Warrant Exercise and Purchase Agreement” attached hereto as Rider
A, properly completed and duly executed, at the principal office of the Company at One Jake Brown Road, Old Bridge, New Jersey
08857, or such other location which shall at that time be the principal office of the Company, and upon payment to the Company
of the Exercise Price multiplied by the number of shares to be purchased upon such exercise. The Exercise Price shall be paid
in immediately available funds to the order of the Company by cashier’s check, certified check or wire transfer. Upon receipt
thereof, the Company shall, as promptly as practicable, execute or cause to be executed and deliver to the Holder a certificate
or certificates as the Holder shall designate representing the number of shares represented by the Holder’s exercise or
in the alternative by the issuance of book-entry shares. Unless and until such time as the Warrant Shares have been registered
under the Securities Act of 1933, as amended (“Securities Act”), certificates representing such Warrant Shares
shall bear restrictive legends. The stock certificate or certificates so delivered shall be in such denominations as may be specified
in said notice and shall be registered in the name of the Holder or in such other name as shall be designated in such notice.
This Warrant shall be deemed to have been exercised and such certificate or certificates shall be deemed to have been issued and
the Holder or such other person so designated shall be deemed to have become a holder of record of such shares for all purposes,
as of the date said notice and payment in full is received by the Company. Unless this Warrant has expired, if this Warrant shall
have been exercised only in part, a new Warrant of like tenor and for such number of shares as the Holder shall direct, representing
in the aggregate the right to purchase a number of shares with respect to which this Warrant shall not have been exercised, shall
also be issued to the Holder within such time.

 

3. Transfer/Warrant
Shares Legend. This Warrant and the rights hereunder shall be non-transferrable, except as permitted by and in compliance
with applicable law. Each certificate representing Warrant Shares shall contain a legend in substantially the following form:

 

THE
SHARES OF COMMON STOCK OF BLONDER TONGUE LABORATORIES, INC. (THE “COMPANY”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR TRANSFERRED
UNTIL (i) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAW AND
SUCH SALE OR TRANSFER IS MADE IN ACCORDANCE WITH SUCH REGISTRATION STATEMENT AND ANY OTHER APPLICABLE STATE SECURITIES LAW OR
(ii) THE COMPANY RECEIVES A WRITTEN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL TO THE HOLDER OF SUCH SHARES OF COMMON
STOCK, PROVIDED SUCH OTHER COUNSEL IS REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER MAY
BE MADE WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

4. Certain
Covenants of the Company. The Company covenants and agrees that all shares which may be issued upon the exercise of this Warrant,
will, upon issuance, be duly and validly issued, fully paid and nonassessable. The Company covenants and agrees that during the
Exercise Periods the Company will at all times have authorized, and reserved for the purpose of issue upon exercise of the purchase
rights evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the rights
represented by this Warrant.

 

5. Anti-Dilution
Provisions. The number and character of the shares underlying this Warrant shall be subject to adjustment only as provided
in this Section 5. In the event of a stock split, stock dividend, reverse stock split or combination of the Common Stock of the
Company, an equitable adjustment shall be made by the Company in the number of shares for which this Warrant has been issued with
respect thereto, and the Exercise Price which must be paid therefor, provided that no such adjustment shall either (i) diminish
the proportionate interest of the Holder prior to the occurrence of the event or (ii) increase the aggregate Exercise Price to
be paid by the Holder upon exercise of the Warrant in full. In addition, in case at any time and from time to time during the
Exercise Periods, the Company shall be a party to any transaction, including, without limitation, a merger, consolidation, liquidation,
combination, reorganization or recapitalization of the Common Stock (each, a “Transaction”), in which the previously
outstanding common stock of the Company shall be changed into or exchanged for different securities of the Company or common stock
or other securities of another corporation (collectively, “Acquiror Common Stock”) or other property (including
cash) or any combination of the foregoing, then in such event: (i) the Warrant shall become fully exercisable notwithstanding
the date of the event and (ii) as often as such event shall occur, as a condition of the consummation of the Transaction, the
Company or the surviving company, as the case may be, shall make lawful and adequate provision so that the Holder, upon the exercise
thereof at any time on or after the consummation of the Transaction during the Exercise Periods, shall be entitled to receive,
and the Warrant shall thereafter represent the right to receive, in lieu of the common stock issuable upon such conversion prior
to such consummation (determined on a fully vested basis), the securities or other property to which the Holder would have been
entitled upon consummation of the Transaction if the Holder had exercised such Warrant immediately prior thereto. There shall
be no preemptive rights associated with the Warrant or the Warrant Shares issuable thereunder.

 

6. Reserved.

 

7. Notice
of Adjustments. Whenever any of the number of shares of Common Stock purchasable or Exercise Price to be paid under the terms
of this Warrant shall be adjusted pursuant to Section 5 hereof, the Company shall notify the Holder at the Holder’s last
address known to the Company.

 

    2

      

    

 

8. Fractional
Shares. No fractional shares of the Company’s Common Stock will be issued in connection with any purchase hereunder
but in lieu of such fractional shares, the Company shall make a cash refund therefor equal in amount to the product of the applicable
fraction multiplied by the Exercise Price.

 

9. Registration
Rights.

 

(a) Piggyback
Rights. If the Company proposes to register any of its Common Stock under the Securities Act in connection with the
public offering of such securities solely for cash (other than in (i) a registration relating to the sale of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration
relating to a transaction under Rule 145 promulgated by the Securities and Exchange Commission (“SEC”) under the
Securities Act; (iii) a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities (as defined below); (iv)
a registration in connection with an offering pursuant to which the Company is seeking to receive less than $2,500,000), the
Company shall, at such time, promptly give the Holder notice of such registration. Upon the request of the Holder, given
within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection
9(b), cause to be registered (x) all of the Common Stock issuable or issued upon exercise of this Warrant and (y) any
Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued
as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clause (x) above (collectively, “Registrable Securities”) that the Holder has requested to be included in
such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section
9 before the effective date of such registration, whether or not the Holder has elected to include Registrable Securities
in such registration. The expenses (other than Selling Expenses (as defined below)) of such withdrawn registration shall be
borne by the Company in accordance with Subsection 9(d).

 

(b) Underwriting
Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant
to Subsection 9(a), the Company shall not be required to include any of the Holder’s Registrable Securities in such
underwriting unless the Holder accepts the terms of the underwriting as agreed upon between the Company and its underwriters,
and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering
by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included
in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering
only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering.

 

(c) Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section
9 with respect to the Registrable Securities of the Holder that the Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required
to effect the registration of the Holder’s Registrable Securities.

 

(d) Expenses
of Registration. All expenses (other than underwriting discounts, selling commissions, and stock transfer taxes applicable
to the sale of Registrable Securities, and fees and disbursements of counsel for the Holder (collectively, “Selling Expenses”))
incurred in connection with registrations, filings, or qualifications pursuant to Section 9, including all registration,
filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company shall be
borne and paid by the Company.

 

(e) Delay
of Registration. Holder shall not have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Warrant as the result of any controversy that might arise with respect to the interpretation or implementation
of this Section 9.

 

    3

      

    

 

(f) Indemnification.
If any Registrable Securities are included in a registration statement under this Section 9:

 

(i)
To the extent permitted by law, the Holder will indemnify and hold harmless the Company, and each of its directors, each of its
officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities
Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), and any controlling Person
of any such underwriter, against any Damages (defined below), in each case only to the extent that such Damages arise out of or
are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf
of the Holder expressly for use in connection with such registration; and the Holder will pay to the Company and each other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained
in this Subsection 9(f) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement
is effected without the consent of the Holder, which consent shall not be unreasonably withheld. For purposes of this Section
9, “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability
(or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required
to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or affiliates) of the Securities Act, the Exchange Act, any state securities law,
or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

(ii)
Promptly after receipt by an indemnified party under this Subsection 9(f) of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim
in respect thereof is to be made against any indemnifying party under this Subsection 9(f), give the indemnifying party
notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and to assume the
defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together
with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one
separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party
by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to
the indemnified party under this Subsection 9(f), to the extent that such failure materially prejudices the indemnifying
party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Subsection 9(f).

 

(iii)
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the
provisions in the underwriting agreement shall control.

 

(iv)
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and the Holder under this Subsection 9(f) shall survive the completion of any offering of Registrable
Securities in a registration under this Section 9, and otherwise shall survive the termination of this Warrant.

 

(g) Termination
of Registration Rights. The right of the Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Subsection 9(a) shall terminate upon such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of the Holder’s shares.

 

    4

      

    

 

10. Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by a form of assignment acceptable
to the Company duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto.

 

11. Investment
Representations. By accepting this Warrant, the Holder represents and warrants to the Company that: (i) this Warrant is being
acquired by the Holder for the Holder’s own account for investment purposes only and (subject to the disposition of its
property being at all times within its control) not with a view to resale, distribution, or other disposition; (ii) any Warrant
Shares which may be issued to the Holder upon exercise of this Warrant will be acquired by the Holder for the Holder’s own
account for investment purposes only and (subject to the disposition of its property being at all times within its control) not
with a view to resale, distribution, or other disposition; (iii) the Holder is able to bear the economic risk of investment in
this Warrant and the Warrant Shares, can afford to sustain a total loss on such investment, and has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of its proposed investment; (iv) when
issued, and upon any exercise of the Warrant, the Holder acknowledges that the Holder is and will be an “accredited investor”
as such term is defined in Rule 501(a) under the Securities Act; (v) the Holder understands that there is no public market for
this Warrant, that there may never be a public market for this Warrant, that in the future there may not be a public or liquid
market for the Warrant Shares, and, therefore, that the Holder may have to bear the risk of its investment in this Warrant and
any Warrant Shares indefinitely; and (vi) subject to Section 5 hereof, the Company shall not be required to issue any of the Warrant
Shares unless such issuance complies with the Securities Act and any applicable state or other securities laws. The Holder understands
and acknowledges that the Company is relying upon the accuracy and truthfulness of these representations and warranties to issue
the Warrant and any Warrant Shares to the Holder.

 

12. Loss,
Theft, Destruction or Mutilation. Upon receipt by the Company of evidence reasonably satisfactory to it that this Warrant
has been mutilated, destroyed, lost or stolen, and in the case of any destroyed, lost or stolen Warrant, a bond of indemnity reasonably
satisfactory to the Company, or in the case of a mutilated Warrant, upon surrender and cancellation thereof, the Company will
execute and deliver in the Holder’s name, in exchange and substitution for the Warrant so mutilated, destroyed, lost or
stolen, a new Warrant of like tenor substantially in the form thereof with appropriate insertions and variations.

 

13. No
Stockholder Rights. The Holder shall not by virtue hereof be entitled to any rights as a stockholder in the Company.

 

14. Definition
of Person. For purposes of this Warrant, “Person” means an individual, corporation, partnership, limited
liability company, trust or other entity.

 

15. Headings.
The descriptive headings of the several sections of this Warrant are inserted for convenience only and do not constitute a part
of this Warrant.

 

16. Governing
Law. This Warrant shall be governed by the substantive laws of the State of Delaware, without regard to principles of conflicts
of law.

 

17. Amendment.
This Warrant may be amended, waived or terminated only by an instrument in writing signed by the Company and the Holder.

 

18. Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant

 

19. Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to the foregoing terms and conditions.

 

    5

      

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be signed by its duly authorized officer on the date of this Warrant.

 

	 	BLONDER
TONGUE LABORATORIES, INC.
	 	 	 
	 	By:	 
	 	 	Edward
R. Grauch, Chief Executive Officer & President
	 	 	 
	 	By:	 
	 	 	Eric
Skolnik, Secretary

 

    6

      

    

 

RIDER
A

 

TO

 

WARRANT
TO PURCHASE _______ SHARES OF COMMON STOCK

OF

BLONDER
TONGUE LABORATORIES, INC.

 

WARRANT
EXERCISE AND PURCHASE AGREEMENT

 

Date: _____________

 

TO:

 

The
undersigned, pursuant to the provisions set forth in the attached Warrant, hereby agrees to purchase _____________________________________
shares of Common Stock covered by such Warrant, and makes payment herewith in full therefor at the price per share provided by
this Warrant.

 

 

	 	By:	 
	 	 	 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]